

Table of Contents

Acknowledgements.....	III
Summary.....	V
List of abbreviations.....	VII
Chapter 1: General Introduction.....	1
1 Schistosomiasis.....	2
1.1 <i>Epidemiology</i>	2
1.2 Biology and life-cycle.....	5
1.3 <i>Pathological and clinical aspects</i>	8
1.3.1 Acute schistosomiasis.....	8
1.3.2 Chronic schistosomiasis.....	8
1.4 <i>Diagnostics</i>	10
1.5 <i>Chemotherapy against schistosomiasis</i>	13
1.6 <i>Intervention and control</i>	14
1.7 <i>Treatment gap</i>	16
1.8 <i>Pharmacokinetic methods</i>	18
1.9 <i>Micro-sampling in pharmacokinetic studies</i>	21
2 Aim and objectives.....	23
2 Chapter 2: <i>In vitro</i> and <i>in vivo</i> activity of R- and S- praziquantel enantiomers and the main human metabolite <i>trans</i>-4-hydroxy-praziquantel against <i>Schistosoma haematobium</i>	35
3 Chapter 3: Pharmacokinetics of praziquantel in <i>Schistosoma mansoni</i> and <i>Schistosoma haematobium</i> infected school- and preschool-aged children.....	47
4 Chapter 4: Evaluation of a novel micro-sampling device, Mitra™, in comparison to dried blood spots, for analysis of praziquantel in <i>Schistosoma haematobium</i>- infected children in rural Côte d'Ivoire.....	74
5 Chapter 5: General Discussion.....	96
6 Chapter 6: General Conclusion.....	120
7 Chapter 7: Appendix:.....	128

7.1 Extrapolation of Praziquantel Pharmacokinetics to a Pediatric Population – A Cautionary Tale.....	133
7.2 Curriculum Vitae.....	178